S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.87 (+0.01%)
AAPL   170.80 (-1.45%)
MSFT   421.36 (-0.02%)
META   490.21 (-0.74%)
GOOGL   150.59 (-0.19%)
AMZN   180.89 (+0.59%)
TSLA   177.56 (-1.26%)
NVDA   906.14 (+0.40%)
NIO   4.62 (-1.07%)
AMD   182.24 (+1.48%)
BABA   72.43 (+1.17%)
T   17.59 (+0.23%)
F   13.22 (+1.23%)
MU   118.27 (-0.73%)
CGC   9.06 (-5.13%)
GE   175.30 (-2.68%)
DIS   122.31 (+1.10%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   67.17 (+0.90%)
XOM   115.50 (+0.46%)
S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.87 (+0.01%)
AAPL   170.80 (-1.45%)
MSFT   421.36 (-0.02%)
META   490.21 (-0.74%)
GOOGL   150.59 (-0.19%)
AMZN   180.89 (+0.59%)
TSLA   177.56 (-1.26%)
NVDA   906.14 (+0.40%)
NIO   4.62 (-1.07%)
AMD   182.24 (+1.48%)
BABA   72.43 (+1.17%)
T   17.59 (+0.23%)
F   13.22 (+1.23%)
MU   118.27 (-0.73%)
CGC   9.06 (-5.13%)
GE   175.30 (-2.68%)
DIS   122.31 (+1.10%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   67.17 (+0.90%)
XOM   115.50 (+0.46%)
S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.87 (+0.01%)
AAPL   170.80 (-1.45%)
MSFT   421.36 (-0.02%)
META   490.21 (-0.74%)
GOOGL   150.59 (-0.19%)
AMZN   180.89 (+0.59%)
TSLA   177.56 (-1.26%)
NVDA   906.14 (+0.40%)
NIO   4.62 (-1.07%)
AMD   182.24 (+1.48%)
BABA   72.43 (+1.17%)
T   17.59 (+0.23%)
F   13.22 (+1.23%)
MU   118.27 (-0.73%)
CGC   9.06 (-5.13%)
GE   175.30 (-2.68%)
DIS   122.31 (+1.10%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   67.17 (+0.90%)
XOM   115.50 (+0.46%)
S&P 500   5,252.29 (+0.07%)
DOW   39,739.39 (-0.05%)
QQQ   444.87 (+0.01%)
AAPL   170.80 (-1.45%)
MSFT   421.36 (-0.02%)
META   490.21 (-0.74%)
GOOGL   150.59 (-0.19%)
AMZN   180.89 (+0.59%)
TSLA   177.56 (-1.26%)
NVDA   906.14 (+0.40%)
NIO   4.62 (-1.07%)
AMD   182.24 (+1.48%)
BABA   72.43 (+1.17%)
T   17.59 (+0.23%)
F   13.22 (+1.23%)
MU   118.27 (-0.73%)
CGC   9.06 (-5.13%)
GE   175.30 (-2.68%)
DIS   122.31 (+1.10%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   67.17 (+0.90%)
XOM   115.50 (+0.46%)

Bionano Genomics (BNGO) Stock Price, News & Analysis

$1.14
+0.05 (+4.13%)
(As of 10:51 AM ET)
Today's Range
$1.09
$1.15
50-Day Range
$1.01
$1.32
52-Week Range
$1.00
$11.80
Volume
354,705 shs
Average Volume
1.59 million shs
Market Capitalization
$62.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Bionano Genomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,832.0% Upside
$21.33 Price Target
Short Interest
Bearish
10.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.35) to ($1.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

741st out of 939 stocks

Analytical Instruments Industry

22nd out of 28 stocks

BNGO stock logo

About Bionano Genomics Stock (NASDAQ:BNGO)

BioNano Genomics, Inc. is a leading life sciences company focused on developing and commercializing innovative solutions for genome analysis. The company's mission is to revolutionize genomics by providing researchers and clinicians with high-resolution, structural variation detection tools to enable a deeper understanding of the genome and its role in human health. BioNano Genomics' flagship product, the Saphyr® system, is a genome imaging platform that comprehensively analyzes structural variations in DNA. By offering a superior alternative to traditional sequencing methods, BioNano Genomics aims to drive advancements in genetic research and facilitate the diagnosis and treatment of genetic diseases.

Headquartered in San Diego, California, BioNano Genomics serves a diverse customer base, including academic and research institutions, pharmaceutical companies, and clinical laboratories worldwide. The company's cutting-edge technology has garnered recognition within the industry, with BioNano Genomics receiving prestigious awards such as the Edison Award for Innovation and the R&D 100 Award for its Saphyr system.

BioNano Genomics boasts a talented and experienced management team that drives the company's vision and strategic initiatives. The Chief Executive Officer, Dr. Erik Holmlin, brings more than 20 years of experience in the life sciences industry and has successfully led the company through significant milestones. Dr. Holmlin holds a Ph.D. in Molecular Biology and has held various executive positions at leading biotechnology companies.

BioNano Genomics has exhibited modest financial performance over the past few years, considering it has not achieved profitability. The company's reported revenue is increasing slowly, but net losses are growing faster than revenue. BioNano Genomics has consistently improved its profit margins, demonstrating its ability to scale operations.

BioNano Genomics' valuation metrics are compelling, indicating favorable investor sentiment. The company's price-to-sales ratio is attractive compared to industry peers, reflecting the market's confidence in its growth prospects. The valuation is driven by BioNano Genomics' disruptive technology, which positions it as a key player in the genomics industry.

BioNano Genomics has experienced significant stock price fluctuations in recent years, with stock prices surging over 200% in Q1 2021 before slowly receding to at or below its original Q1 2021 price. 

BioNano Genomics operates in the genomics industry, which is experiencing rapid growth and technological advancements. The increasing demand for genome analysis tools, driven by research initiatives and the rising prevalence of genetic diseases, presents a significant market opportunity. While the genomics industry offers considerable growth prospects, it is also highly competitive. BioNano Genomics faces competition from established players and emerging companies in the field. Key competitors include Illumina Inc., Pacific Biosciences of California Inc., and Oxford Nanopore Technologies Ltd. These companies offer sequencing technologies that compete with BioNano Genomics' Saphyr system.

However, BioNano Genomics differentiates itself by focusing on structural variation analysis, which provides valuable insights into complex genomic rearrangements that traditional sequencing methods may miss. The Saphyr system's ability to accurately detect large-scale structural variations positions BioNano Genomics as a leader in this niche market segment. The company's commitment to innovation and ongoing product enhancements gives it a competitive edge.

To strengthen its competitive positioning, BioNano Genomics actively collaborates with research institutions and key opinion leaders in the genomics field. These partnerships facilitate the validation and adoption of the Saphyr system while also contributing to the company's research and development efforts.

BioNano Genomics has several growth opportunities on the horizon. The company aims to expand its customer base by targeting new markets and geographies. Additionally, BioNano Genomics continues to invest in research and development to enhance the capabilities of the Saphyr system and develop new applications for its technology.

One significant growth opportunity lies in the clinical diagnostics market. The Saphyr system has demonstrated promising results in identifying structural variations associated with various genetic diseases, including cancer. As the clinical utility of the Saphyr system becomes more evident through clinical trials and validations, BioNano Genomics can penetrate the diagnostics market and collaborate with healthcare providers to improve patient care and treatment outcomes.

Furthermore, BioNano Genomics may consider strategic acquisitions or partnerships to complement its existing product portfolio and expand into adjacent market segments. By leveraging its expertise in structural variation analysis, the company can explore partnerships with pharmaceutical companies for drug discovery and development programs.

While BioNano Genomics is poised for growth, it faces risks and challenges. Regulatory factors play a crucial role in the genomics industry, and changes in regulations related to genomic testing, data privacy, or reimbursement policies could impact the company's operations. BioNano Genomics must stay abreast of regulatory developments and adapt its strategies accordingly.

Additionally, technological advancements and evolving customer preferences pose challenges. BioNano Genomics must continuously innovate and enhance its products to stay ahead of competitors and meet customer expectations. Failure to do so could result in a loss of market share.

Moreover, market acceptance and adoption of the Saphyr system remain key challenges. While the system has gained traction, broader adoption by research institutions and clinical laboratories is necessary for sustainable growth. BioNano Genomics must actively educate potential customers about the advantages of its technology and build a strong customer support infrastructure to drive adoption.

BNGO Stock Price History

BNGO Stock News Headlines

BNGO Apr 2024 4.000 call
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
BioNano Genomics (BNGO) Gets a Hold from Maxim Group
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Q4 2023 Bionano Genomics Inc Earnings Call
BNGO Mar 2024 1.000 put
BNGO Mar 2024 1.500 put
SNDL Feb 2024 1.000 put
IDEX Feb 2024 1.500 call
7 Penny Stocks to Buy on the Dip: February 2024
SNDL Feb 2024 1.000 call
See More Headlines
Receive BNGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:BNGO
Fax
N/A
Employees
344
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.33
High Stock Price Target
$48.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,857.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-232,490,000.00
Net Margins
-643.74%
Pretax Margin
-643.57%

Debt

Sales & Book Value

Annual Sales
$36.12 million
Book Value
$2.10 per share

Miscellaneous

Free Float
53,359,000
Market Cap
$59.61 million
Optionable
Optionable
Beta
2.36
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Robert Erik Holmlin M.B.A. (Age 56)
    Ph.D., President, CEO, Secretary & Director
    Comp: $834.57k
  • Mr. Mark Oldakowski (Age 50)
    Chief Operating Officer
    Comp: $603.82k
  • Dr. Alka Chaubey FACMG (Age 51)
    Ph.D., Chief Medical Officer
    Comp: $558.83k
  • Ms. Gulsen Kama M.B.A.
    Chief Financial Officer
  • Mr. Mark Adamchak CPA
    VP of Accounting & Controller
  • Mr. Jonathan Dixon J.D. (Age 49)
    General Counsel
  • Mr. Stanislas Marin M.B.A.
    M.S., Vice President of Global Sales
  • Ms. Donna Polizio
    Global Head of Market Access
  • Mr. Cory Kreeck
    Global Head of People Operations
  • Dr. Klint Rose Ph.D.
    Head of Research & Development

BNGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bionano Genomics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNGO shares.
View BNGO analyst ratings
or view top-rated stocks.

What is Bionano Genomics' stock price target for 2024?

3 analysts have issued 1-year target prices for Bionano Genomics' shares. Their BNGO share price targets range from $6.00 to $48.00. On average, they expect the company's share price to reach $21.33 in the next year. This suggests a possible upside of 1,832.0% from the stock's current price.
View analysts price targets for BNGO
or view top-rated stocks among Wall Street analysts.

How have BNGO shares performed in 2024?

Bionano Genomics' stock was trading at $1.89 on January 1st, 2024. Since then, BNGO shares have decreased by 41.6% and is now trading at $1.1042.
View the best growth stocks for 2024 here
.

When is Bionano Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BNGO earnings forecast
.

How were Bionano Genomics' earnings last quarter?

Bionano Genomics, Inc. (NASDAQ:BNGO) announced its quarterly earnings data on Tuesday, August, 3rd. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.20. The company had revenue of $3.86 million for the quarter, compared to analyst estimates of $3.30 million. Bionano Genomics had a negative net margin of 643.74% and a negative trailing twelve-month return on equity of 103.68%.

What ETFs hold Bionano Genomics' stock?

ETFs with the largest weight of Bionano Genomics (NASDAQ:BNGO) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Global X Telemedicine & Digital Health ETF (EDOC).Global X Genomics & Biotechnology ETF (GNOM).

When did Bionano Genomics' stock split?

Shares of Bionano Genomics reverse split on the morning of Monday, August 7th 2023. The 1-10 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Bionano Genomics issued on next quarter's earnings?

Bionano Genomics updated its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.3 million-$8.8 million, compared to the consensus revenue estimate of $9.7 million.

What is R. Erik Holmlin's approval rating as Bionano Genomics' CEO?

17 employees have rated Bionano Genomics Chief Executive Officer R. Erik Holmlin on Glassdoor.com. R. Erik Holmlin has an approval rating of 73% among the company's employees. 71.0% of employees surveyed would recommend working at Bionano Genomics to a friend.

What other stocks do shareholders of Bionano Genomics own?
When did Bionano Genomics IPO?

Bionano Genomics (BNGO) raised $16 million in an IPO on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Bionano Genomics' major shareholders?

Bionano Genomics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.88%), Vanguard Group Inc. (4.88%), Quadrature Capital Ltd (0.29%), Quadrature Capital Ltd (0.20%), Northern Trust Corp (0.28%) and Dimensional Fund Advisors LP (0.25%). Insiders that own company stock include Christopher P Stewart, Hannah Mamuszka, R Erik Holmlin and Yvonne Linney.
View institutional ownership trends
.

How do I buy shares of Bionano Genomics?

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNGO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners